Australia markets open in 2 hours 24 minutes

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
137.73-0.07 (-0.05%)
At close: 4:00PM EDT

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000

Full-time employees743

Key executives

NameTitlePayExercisedYear born
Mr. Douglas S. IngramPres, CEO & Director1.39MN/A1963
Mr. William F. CiambroneExec. VP of Technical Operations438.01kN/A1964
Mr. David Tyronne Howton Jr.Exec. VP, Gen. Counsel & Corp. Sec.731.8k16.43M1972
Dr. Gilmore O'Neill M.D.Exec. VP of R&D and Chief Medical Officer933.33kN/A1965
Mr. Joseph BraticaController, VP and Interim Principal Financial & Accounting OfficerN/AN/A1964
Mr. Ian M. EstepanSr. VP of Corp. Affairs & Chief of StaffN/AN/AN/A
Dr. Diane L. BerrySr. VP of Global Health Policy and Gov. & Patient AffairsN/AN/AN/A
Mr. Alexander G. CumboExec. VP & Chief Commercial OfficerN/AN/A1971
Ms. Joan Nickerson M.B.A.Sr. VP of HRN/AN/AN/A
Dr. Louise Rodino-Klapac Ph.D.Sr. VP of Gene TherapyN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Sarepta Therapeutics, Inc.’s ISS governance QualityScore as of 6 October 2020 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.